FDA Schedules Hearing on Drug-Suicide Link
<i> Reuters</i>
WASHINGTON — The question of whether Prozac, the world’s best-selling anti-depressant drug, has been a factor in patient suicides will be probed at a public hearing next month, government regulators and drug industry executives said Wednesday.
Industry analysts said the Food and Drug Administration called the Sept. 20 meeting to allay public fears about Prozac. Claims that the medication induces suicide have been the subject of extensive media attention.
Sign up for Essential California
The most important California stories and recommendations in your inbox every morning.
You may occasionally receive promotional content from the Los Angeles Times.
